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Abstract
For many complex diseases, an earlier and more reliable diagnosis is considered a key prerequisite for developing more
effective therapies to prevent or delay disease progression. Classical statistical learning approaches for specimen classifica-
tion using omics data, however, often cannot provide diagnostic models with sufficient accuracy and robustness for
heterogeneous diseases like cancers or neurodegenerative disorders. In recent years, new approaches for building
multivariate biomarker models on omics data have been proposed, which exploit prior biological knowledge from molecular
networks and cellular pathways to address these limitations. This survey provides an overview of these recent
developments and compares pathway- and network-based specimen classification approaches in terms of their utility for
improving model robustness, accuracy and biological interpretability. Different routes to translate omics-based multifactor-
ial biomarker models into clinical diagnostic tests are discussed, and a previous study is presented as example.
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Introduction
In spite of the remarkable advances in biomedicine over recent
decades, for a wide range of common, systemic and chronic dis-
eases, precise molecular markers for early diagnosis are not yet
available. In particular, for some of the most prevalent neuro-
logic disorders (e.g. Alzheimer’s [1] and Parkinson’s disease [2])
and cancer types (e.g. colorectal cancer [3] and lung cancer [4]),
diagnostic tools are often only applicable in the late symptom-
atic stages of the disease, provide insufficient sensitivity or spe-
cificity or fail to detect clinically relevant disease subtypes. As a
consequence, inadequate therapies may be prescribed, treat-
ment could often start too late to prevent irreparable damage
and the development of new and more effective therapies for
early intervention is hampered by misdiagnosed individuals in
the study cohorts. While alternative diagnostic approaches can-
not be expected to fully address all of these issues, improve-
ments in only one of these aspects could already have
significant benefits for patients. Even for infectious diseases
with relatively unambiguous symptoms, new diagnostic tools
may be required because during the incubation period a clear
distinction between contagious and uninfected individuals is
usually not possible (e.g. this has been a major issue during the
recent Ebola virus disease outbreak in Africa [5]).
Classical molecular diagnostic tests measure the abundance
of only a single biomolecule, e.g. to diagnose prostate cancer,
plasma levels of the prostate-specific antigen (PSA) are com-
monly assessed. Although these approaches have advantages
in terms of simplicity and costs, for complex and heterogeneous
diseases, single-molecule biomarkers tend to provide insuffi-
cient accuracy and robustness across different patient cohorts
(even the widely accepted PSA test for prostate cancer has a lim-
ited sensitivity of 72.1% according to a meta-analysis [6]).
Building multivariate biomarker models derived from high-
throughput omics measurements, e.g. using DNA or protein
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microarrays, would, in principle, offer the potential to account
for diverse subtypes or facets of diseases, provided that the
studied disorder is characterized by heterogeneous molecular
manifestations. However, limitations of these high-throughput
techniques (e.g. random noise and systematic biases, lack of ro-
bustness and reproducibility) and statistical limitations in the
analysis of high-dimensional data (e.g. the multiple testing
problem [7], feature redundancy and interdependence [8, 9] and
issues summarized as the ‘curse of dimensionality’ [10, 11])
often prevent the discovery of genuine and reproducible pat-
terns for diagnostic specimen classification.
In recent years, new bioinformatics approaches have
therefore been proposed, which involve the integration of prior
biological knowledge from cellular pathways and molecular net-
works into the model-building procedure. These approaches
make use of prior observations, according to which, differences
in pathway activity between diverse biological conditions tend to
be more stable than differences in individual gene activity [12],
and disease-associated biomolecular changes tend to be coordi-
nated and display grouping patterns within molecular subnet-
works [13]. The main rationale is that by exploiting these patterns
as prior information when building prediction models, spurious
discriminative structures in the data can be recognized and more
robust and coherent patterns at the pathway- and network-level
are selected instead of predictive features. Although a wide range
of corresponding machine learning methods is already available,
the benefits and limitations of different approaches are not al-
ways clear, and an overview on which strategies are adequate for
which specific goals or applications is lacking.
Here, a review of recent network- and pathway-based statis-
tical learning approaches for high-throughput omics data set
analysis is provided, including a critical discussion of limita-
tions and the added value of different methodologies for
improving model robustness, accuracy and biological
interpretability. Because not all diseases are characterized by
aberrant molecular signatures, the application focus is on diag-
nostic approaches for diseases with complex molecular mani-
festations. First, methods using information from public
cellular pathway definitions will be discussed, then approaches
exploiting prior knowledge from genome-scale molecular
networks. Next, common limitations of pathway- and network-
guided predictive modeling are pointed out, as well as
shortcomings related to the biospecimen origin, processing and
storage and possible techniques to address or alleviate limita-
tions in data analysis. Finally, the potential for translating
omics-derived multivariate sample classification models into
chip-based diagnostic devices is discussed, and a previous
success story is presented.
Pathway-based biomarker modeling
Cellular pathway definitions from manually curated databases,
including KEGG [14], BioCarta [15], WikiPathways [16], Reactome
[17] and PID [18], are frequently used knowledge sources for bio-
logical data interpretation. These pathways are typically de-
signed in a subjective manner, often using incomplete
information and inconsistent criteria for judging the relevance
of putative pathway members (see ‘Limitations and possible
solution strategies’ section), but this does not affect the meth-
odological principles of pathway analysis, and results provided
by robust analysis techniques are not significantly altered by
small variations in pathway definitions. In particular, enrich-
ment analysis methods [19–23] and pathway activity visualiza-
tion tools [24, 25] are commonly applied to exploit information
from these databases and obtain a better understanding of
pathway-level molecular alterations in omics data. The utility
of pathway information for biomarker discovery has also been
recognized early [26], and more recently, a variety of bioinfor-
matics approaches have been proposed to directly integrate
knowledge from pathways into predictive model building for
omics sample classification.
These methods mainly differ in terms of their pathway ac-
tivity scoring approach (i.e. the approach used to summarize
and score biomolecular activity data for cellular pathways as
predictive features for classification tasks, e.g. via different di-
mension reduction methods, see discussion below) and the pre-
diction method used (i.e. the machine learning algorithm
applied to the summarized pathway activity scores to build a
sample classification model). Table 1 shows an overview of dif-
ferent methodologies and their main characteristics, described
in more detail as follows.
Averaging and dimension reduction approaches
to score pathway activity
One of the first machine learning approaches for high-through-
put data analysis guided by pathway knowledge was proposed
by Guo et al. [27]. Their method classified microarray cancer
samples by computing mean or median expression levels of the
gene members in biological process modules from the Gene
Ontology (GO) database as input for a decision tree classifier
[36]. This straightforward averaging approach was already re-
ported to provide benefits in terms of robustness to measure-
ment noise and comparable or better classification performance
on cancer microarray data as compared with conventional
gene-level analyses.
Soon thereafter, other research groups explored whether al-
ternative ways to summarize molecular activity data in path-
ways could exploit the information content more effectively.
Tomfohr et al. [28] showed that applying a dimension reduction
approach, Singular Value Decomposition (SVD), to gene expres-
sion levels of pathway members and using the first eigenvector
(called ‘meta-gene’) to derive a pathway activity representation,
enabled the discovery of statistically significant pathway alter-
ations in disease-related microarray data sets.
Because only a subset of pathway members may be involved
in disease-associated changes, Lee et al. [29] later proposed to
score pathway activity by focusing on condition-responsive
genes (CORGs) within pathways. They applied a greedy search
algorithm to find a gene subset that maximizes a t-statistic
score for sample class discrimination, using a weighted sum of
normalized gene expression levels for the selected input genes.
On multiple microarray cancer data sets, the CORG-based path-
way predictors provided increased discriminative power in
comparison with gene-based classification, and the rankings of
pathway alterations were more reproducible when tested across
100 alternative 2-fold splits of each data set.
A first probabilistic method to infer pathway activity from
omics data was developed by Su et al. [30]. It estimates the log
likelihood ratio (LLR) between different phenotype hypotheses
(e.g. disease or control) from the expression level of each path-
way member gene i (LLRi¼ log[fi1(xij)/ fi2(xij)], where fiy(x) is the
conditional probability density function of gene i under pheno-
type y), and then uses these ratios for a weighted combination
of expression levels into a summarized pathway activity finger-
print aj (aj¼Rin LLRi (xij)), assuming independent contributions
of the LLRs for different member genes. The authors compared
their approach on two breast cancer data sets against gene-level
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predictors, the mean/median pathway summarization, the
SVD- and CORG-based techniques described above, and their
method achieved the highest predictive performance in both
within-data set cross-validation experiments and one out of
two cross-data set prediction experiments (the mean summar-
ization scored higher in one case).
While the techniques discussed above mostly summarize
pathway activity via (weighted) averages or dimension reduc-
tion approaches, it was noted that disease-associated pathway
alterations may affect the variance of expression levels in path-
ways more strongly than the mean. Generally, variance pat-
terns in disease-related omics data can reflect inter-patient
variation (e.g. differences in the etiology or disease stage) or
intra-patient fluctuations (e.g. on/off phases as those observed
in Parkinson’s disease or imbalances in the activity of specific
cellular pathways), and the study of both of these sources of
variation may be important to improve the understanding of
the disease. Glaab et al. [31] therefore proposed a variance-based
approach to identify discriminative pathway signatures,
providing a possibility to account for variation in the activity of
cellular processes for a single patient and for variation across
multiple individuals, and combined it with diverse classification
approaches as part of a public Web application. Apart from
modifying the pathway activity representation, they developed
a rule-based learning method comparing activities in pairs of
pathways rather than comparing activities of single pathways
against fitted threshold values to increase the robustness of
pathway-based classification models [37]. Rule-based models
have high stability with regard to small variations in the input
data and facilitate the biological interpretation of prediction
models by using only combinations of simple if-then-else rules
for sample classification [38].
A further strategy to improve classifier robustness is to use
discretized pathway activity scores or counting statistics, e.g.
Svenson et al. [32] presented an approach that first determines
how many genes are up- or downregulated in a pathway using a
predefined fold-change threshold. This information was com-
bined into a ratio score, which equals 1 if all pathway members
are upregulated, 0 if equal numbers of genes are up- and
downregulated, and 1 if all genes are downregulated. After
computing this ratio score for all pathway gene sets and train-
ing samples from a microarray case-control study, they applied
nearest centroids classification to the pathway ratio scores to
classify new test set samples. In comparison with gene-level
classification, they report that the proposed classification ap-
proach performed better for all tested training set sizes.
Graph-based and hierarchical pathway activity scoring
Cellular pathway diagrams do not only capture information on
the functional relatedness of biomolecules involved in a path-
way, but also on the network topology of regulatory or molecu-
lar interactions that link them together.
Efroni et al. [33] presented one of the first pathway analysis
approaches, which not only scores pathway activities in omics
data, but also the consistency of molecular activities within
pathways, given the topology of interactions between their
members. Considering the input and output genes for a regula-
tory interaction, their probabilities of being in an under- or
overexpressed state in a condition of interest can be estimated
from gene expression measurements, although noise in the
data may make the estimates highly uncertain. A consistency
score can then be obtained by comparing the state probabilities
for output genes against their inferred state probabilities,
derived from the estimated states of the interconnected input
genes and the probability of the relevant interactions to be ac-
tive or inactive. Thus, averaged pathway consistency scores can
be computed and used as predictive features in combination
with pathway activity scores to classify biological samples rep-
resenting different conditions. Evaluating this approach on
Table 1. Overview of pathway-based machine learning approaches for supervised classification of omics samples
Publication Pathway activity scoring method Prediction method
Guo et al. [27] Mean or median expression levels in GO modules Decision tree classification
Tomfohr et al. [28] Expression levels are summarized via the first eigenvector
from SVD analysis
Focus on predictive feature selection via
t-statistics (any classifier is applicable)
Lee et al. [29] Normalized sum of expression levels for CORGs within
pathways
Logistic regression
Su et al. [30] Weighted sum of LLRs for pathway members Logistic regression or linear discriminant
analysis
Glaab et al. [31] Variance across pathway member activity is quantified and
compared instead of averaged pathway activity
SVM, random forest, nearest shrunken centroid
classifier or ensemble learning
Svenson et al. [32] For each gene set and patient a ratio score is defined de-
pending on the number of up- and down-regulated mem-
bers in the gene set
Nearest centroids classification
Efroni et al. [33] Joint scoring of pathway activity and consistency using
interactions within pathways
Bayesian linear discriminant classifier
Vaske et al. [34] Probabilistic inference is used to predict pathway activities
from a factor graph model of genes and their products
Cox proportional hazard regression (survival
prediction)
Breslin et al. [35] Signal transduction pathways with directional interactions
are used to define the activity of a pathway based on the
average expression of its downstream target genes
No classification is performed, but contingency
tables show associations between sample-
wise pathway activity and clinical sample
classifications
Kim et al. [12] Hierarchical feature vectors are used, assigning a two-level
hierarchical structure to the features/genes determined
by their pathway membership
SVM
Averaging and dimension reduction approaches are listed on top, whereas graph-based and hierarchical pathway activity scoring methods are listed below the bold
black line.
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microarray cancer data by using the new pathway-level features
as input for a Bayesian Linear Discriminant Classifier, the au-
thors obtained similar or better predictive performance as com-
pared with previously reported results for the test data.
Pathway topology information is also exploited in the approach
by Vaske et al. [34], who converted cellular pathway diagrams into
a factor graph model, describing the interactions between the
involved biomolecules. The method can integrate information
from different types of omics data for a biological sample and uses
an Expectation Maximization (EM) algorithm to infer probabilistic
pathway activity scores for each pathway/sample combination.
When applying the approach to glioblastoma multiform gene ex-
pression and copy number data and grouping patients based on
their pathway alterations, the identified subgroups displayed sig-
nificant differences in quantitative survival in a Kaplan–Meier ana-
lysis. Robust patient stratification results were only obtained using
the pathway-based scores and not via gene-level analyses.
Apart from considering the topology of molecular interactions
within a pathway, studying alterations in all the downstream tar-
gets of pathway members (i.e. including targets not belonging to
the pathway) may provide an additional source of information to
further improve pathway activity scoring. Breslin et al. [35] pre-
sented a corresponding downstream analysis approach, which
detects variation in pathway activity from the degree of correl-
ation between downstream targets of a pathway. Using two cor-
relations scores, one considering all pairs of downstream targets,
and one considering only pairs without common transcription
factors, they identified several differentially active pathways in
microarray data from case-control studies. Additionally, they
defined an activity score for pathways based on the average ex-
pression of their downstream target genes, and showed that the
sample-wise activities for several pathways are significantly
associated with clinical sample classifications.
Finally, although all approaches considered so far use pathway-
level sample classification as a replacement for gene-level classifi-
cation, these are not exclusive options. Kim et al. [12] proposed to
build biomarker models from gene expression data at two levels,
the gene and pathway level, via a hierarchical feature structure.
This structure organizes the individual gene-level features into se-
cond-level aggregate features (pathways), used by a support vector
machine (SVM) algorithm to classify samples. The authors con-
sidered three alternative approaches: GLEG (GSEA-based Leading
Edge Gene feature method, using predictor genes derived from
gene set enrichment analysis [19], which as a group maximally dif-
ferentiate between the sample classes), GPF (GSEA Pathway Feature
method, using enriched pathways as features) and SPF (SVM-based
Pathway Feature method, using pathway features derived from
SVM). When comparing these methods against classical gene-level
and random gene set predictors, using cross-validation and cross-
study prediction on microarray cancer data, in the majority of
cases, the newly proposed methods achieved better results.
In summary, a wide range of pathway activity inference
methods and machine learning approaches are available, which
can be combined effectively for pathway-based diagnostic
classification of biological samples. While pathway-based
prediction does not necessarily provide superior predictive per-
formance in within-data set cross-validation experiments,
improved robustness and accuracy was observed consistently
in cross-study prediction tasks.
Network-based biomarker modeling
Although manually curated pathways have many benefits for
the biological interpretation of large-scale omics data, in living
cells, metabolic and signaling pathways are not isolated but
interconnected within large and complex molecular and regula-
tory networks. These networks often include several genes, pro-
teins or metabolites that are not annotated for any pathway
and therefore ignored by pathway-based analysis methods.
Consequently, to identify disease-associated modules of inter-
connected biomolecules in a more unbiased manner (i.e. with-
out restricting the search space to biomolecules with known
pathway annotations), network-based analysis methods have
been introduced. While pathway-based approaches for bio-
marker modeling may have advantages in terms of model inter-
pretability, the search space exploration in network-based
biomarker discovery is not restricted by subjectively defined
pathway boundaries, and the genome-scale molecular networks
used as input typically cover significantly larger numbers of bio-
molecules than all combined pathways. Nevertheless, similar to
subjectively defined pathways, networks assembled from public
data sources suffer from various limitations, e.g. missing mo-
lecular interactions and lack of tissue-specific annotations, and
these issues have to be addressed by dedicated methods (see
section on ‘limitations and possible solution strategies’ below).
In the following, two main types of network-based modeling
approaches will be discussed: First, two-step sequential
approaches, which score the activity in molecular subnetworks
and afterward use these activities for predictive machine learn-
ing; and secondly, one-step network analysis approaches,
which exploit network topology information directly within the
predictive model building.
Two-step network activity scoring and prediction
approaches
Network activity over multiple interconnected biomolecules
can be summarized and scored using similar averaging or di-
mension reduction approaches as in pathway activity scoring
methods. However, in contrast to the straightforward use of
predefined pathway definitions, first a molecular or regulatory
network has to be assembled or reconstructed, using either pub-
lic molecular interaction databases or applying network infer-
ence methods to omics data (in Table 2, an overview of different
methodologies is shown, which are discussed in the following).
A first method to construct new sample-specific gene regu-
latory networks for transcriptomics sample classification was
proposed by Tuck et al. [39]. The networks were generated by
determining the graph-theoretic intersection between a static
connectivity network (representing transcription factor binding
to gene promoter regions), obtained using data from the
TRANSFAC database [50], with sample-specific coexpression
networks (representing transcription-factor–target gene
coexpression), derived from gene expression data. To extract
discriminative features for diagnostic specimen classification
from these networks, they proposed a link-based classification
approach, comparing the activity status of gene regulatory
interactions (called ‘links’) across different sample groups, and
a degree-based classification method, comparing topological
centrality measures [51] for the networks. When testing these
approaches on data from different cancer case-control studies,
high cross-validated accuracies were reported for both cell type
and patient sample classification. Moreover, the network-based
analysis enabled the authors to identify key transcriptional
regulators altered under specific disease conditions.
Instead of constructing new regulatory networks, discrim-
inative disease-associated network alterations can also be iden-
tified by computationally mapping omics data onto in silico
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representations of biochemical protein–protein interaction (PPI)
networks. Ma et al. [40] developed a corresponding approach to
obtain more reliable disease association scores for genes by ex-
ploiting neighborhood information from a PPI network. They
used a modified Pearson correlation coefficient to assess the as-
sociation between microarray gene expression and numeric val-
ues encoding the disease status of the samples (taking into
consideration that these phenotype values may not have a nor-
mal distribution) and assigned the Fisher-transformed gene-
phenotype association scores to the corresponding proteins in a
PPI. Next, they recalibrate these association scores by modeling
the underlying true scores for each gene using Markov Random
Field theory [52], reestimating their values from weighted con-
tributions of their network neighbors’ original association
scores (the weights are determined according to different net-
work neighborhood definitions, using either direct neighbors,
shortest path or diffusion kernel neighborhoods, see [40] for
details). When evaluating the utility of the recalibrated scores
for disease gene prioritizations on microarray data using known
Gene Ontology functional annotations, conventional
prioritization approaches using only gene expression or PPI data
were outperformed (although the scoring approach could also
be used for predictive model building, this particular application
was not considered).
While the approach by Ma et al. focuses on improving the
disease-association scores for individual genes, Chuang et al.
[41] presented a method identifying and scoring entire disease-
related subnetworks, similar to their pathway association scor-
ing approach discussed above (see Lee et al. [29]). After comput-
ing the mutual information (MI) between sample phenotype
values (encoding the presence or absence of a disease) and dis-
cretized expression values for each gene from a microarray data
set assigned to the proteins in a PPI, they applied a greedy
search to expand the seed nodes in the network with locally
maximal MI scores. Specifically, each seed node was expanded
such that the sum of scores for the expanded network module
is maximized (the search stops when no extension increases
the total score above a predefined improvement rate). When
training logistic regression classifiers on the normalized and
averaged activities of the resulting subnetworks for breast
Table 2. Overview of network-based methods for machine learning analysis of omics data sequential network activity scoring and prediction
methods are shown on top, whereas machine learning approaches using embedded network-based feature selection are listed below the bold
black line
Methodology
publication
Network activity/alteration scoring method Prediction method
Tuck et al. [39] Sample-specific gene regulatory networks are constructed and
subnetwork activity is scored by summing over active
interactions
Nearest neighbors, decision tree, Naı¨ve
Bayes, among others
Ma et al. [40] Disease association is scored for genes based on gene expres-
sion data and their neighbors’ association scores in a PPI net-
work using Markov Random Field theory
The approach is evaluated for disease gene
prioritization but is applicable for predict-
ive feature selection in combination with
any prediction method
Chuang et al. [41] Normalized gene expression data is mapped onto a protein
interaction network and discriminative subnetworks are
identified via a greedy search procedure
Logistic regression
Taylor et al. [42] Hub nodes in protein interaction networks are determined and
the relative gene expression of hubs with each of their inter-
acting partners is computed to identify hubs with diverse
relative expression across sample groups
Affinity propagation clustering is used to as-
sign a probability of poor prognosis to
breast cancer patients
Petrochilos et al. [43] A random walk community detection algorithm is applied to
discover modules in a molecular interaction network, and
gene expression data is used to identify disease-associated
modules
The approach is used to identify cancer-asso-
ciated network modules and validated by
scoring the enrichment of known cancer-
related genes extracted from the OMIM
database
Rapaport et al. [44] Spectral decomposition of gene expression profiles is applied
with respect to the eigenfunctions of a network graph,
attenuating the high-frequency components of the expres-
sion profiles with respect to the graph topology
SVM
Li et al. [45] A network-constrained regularization procedure for linear re-
gression analysis is used to identify disease-related discrim-
inative subnetworks
Penalized linear regression
Yang et al. [46] Three machine learning methods for graph-guided feature se-
lection and grouping are proposed, including a convex func-
tion and two non-convex formulations designed to reduce
the estimation bias
Penalized least squares-based approach
(GOSCAR: Graph octagonal shrinkage and
clustering algorithm for regression)
Lorbert et al. [47, 48] A sparse regression approach is proposed, using the PEN pen-
alty to favor the grouping of strongly correlated features
based on pairwise similarities (e.g. derived from a molecular
interaction graph)
Penalized regression (PEN penalty)
Vlassis et al. [49] Penalized logistic regression is applied using a convex PEN pen-
alty function (see approach by Lorbert et al.) with absolute
feature weights to better reflect the relevance of discrimina-
tive genes in the feature selection
Penalized logistic regression (PEN penalty
with absolute feature weights)
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cancer data, the authors found that the subnetwork markers
were more reproducible than single-gene markers and
provided higher accuracy in distinguishing metastatic from
nonmetastatic tumors.
As an intermediate solution between focusing on individual
biomolecules and entire network modules, Taylor et al. [42] pro-
posed a method that investigates network nodes with outstand-
ing topological properties and their direct neighbors. After
computationally mapping breast cancer gene expression data
onto the in silico representation of a PPI network, they deter-
mined proteins with large numbers of biochemical interaction
partners (so-called ‘hub nodes’), and computed their relative ex-
pression compared with each of these interacting partners.
They then determined for which hubs the relative expression
differed significantly between long-term survivors and patients
who died from the disease, and applied a clustering approach to
assign a probability of poor prognosis to new patient samples
(the specific method used is known as ‘affinity propagation
clustering’ in the literature). The approach was evaluated using
5-fold cross-validation, providing accuracy, sensitivity and spe-
cificity estimates that compared favorably with the reported
results for commercially available genomic breast cancer
diagnostics.
Instead of considering topological properties of individual
nodes in a molecular network, information from a network
graph can also be extracted via algorithms for finding sub-
graphs, which stand out in terms of their high density of
molecular interactions (using approaches referred to as ‘com-
munity identification’ or ‘graph clustering’ methods in the lit-
erature). Petrochilos et al. [43] proposed a corresponding
approach, which first applies a graph-based random walk algo-
rithm on a genome-scale molecular network. Information from
cancer-related gene expression data was then integrated into
the network by setting the weight of each network node as the
maximum fold change of probes corresponding to its gene sym-
bol (weights for biochemical interactions are determined by the
square of the mean of the absolute fold changes of the relevant
interaction partners). Finally, the score of a network module of
connected nodes was obtained by comparing its cumulative ac-
tivity (i.e. the square of the average weighted expression for all
its nodes) against a bootstrap distribution of cumulative activ-
ities obtained via random sampling of a matched number of
fold change values. When testing the enrichment of known can-
cer genes in the top-scored network modules identified with
this approach, a similar or better performance was reached in
comparison with other widely used module-finding algorithms
(potential alternative applications of the identified modules for
biomarker modeling were not assessed in this publication).
Apart from averaging molecular activities over network
neighborhoods or using community identification methods, sig-
nal processing techniques may provide a further means to glean
useful information from a network for predictive model build-
ing, as shown in an approach by Rapaport et al. [44]. They made
use of the observation that genes in close proximity to each
other in a network tend to have similar expression and pro-
posed to denoise microarray measurements by removing their
high-frequency component over the network. For this purpose,
spectral decomposition of gene expression profiles with respect
to a molecular network graph was applied, followed by attenu-
ating high-frequency signal components, expected to represent
measurement noise. The method was evaluated for supervised
analysis of irradiated and nonirradiated yeast strains using a
SVM, providing similar classification performance as a model
built without the network-based filtering, but facilitating
biological data interpretation by grouping the selected biomol-
ecules according to their participation in the network modules.
One-step machine learning approaches for network
analysis
In contrast to the network analysis approaches considered so
far, which apply network feature extraction and predictive ma-
chine learning analysis in separate steps, more recently, one-
step network-based feature selection approaches have been
proposed, integrating the attribute selection directly into the
predictive model building. Most of these approaches formulate
the model building task as an optimization problem formula-
tion, in which the objective function for classification or regres-
sion is extended by a penalty term promoting the selection of
grouped features in a molecular network (this strategy is also
referred to as network-constraint regularization).
Li et al. [45] proposed one of the first corresponding
approaches by adding a penalty term to linear regression, incor-
porating network information into the analysis via the
Laplacian matrix of the network graph. The approach penalizes
the L1-norm of the feature weights and encourages a smooth
profile of weights over neighboring nodes in the network.
However, Binder and Schumacher later reported that the
method has lower performance than a null model, i.e. a model
not using any covariate information [53]. As possible explan-
ations, they note that Li et al. discarded censored observations
and about 20 000 variables that could not be assigned to corres-
ponding nodes in the molecular interaction network (see sec-
tion on ‘limitations’ below). Yang et al. [46] suggested that the
previously used network grouping penalties can introduce add-
itional estimation bias into the model when the coefficient
signs for two features connected in the graph are different.
They presented alternative penalties to achieve network group-
ing and sparse feature selection, in particular two non-convex
penalties, which shrink only small differences in absolute val-
ues of feature weights to reduce the estimation bias [46]. In ex-
periments on synthetic data and two real data sets, the new
approaches outperformed previous feature grouping methods.
However, with non-convex penalties, finding global optimal
solutions is often not feasible and even identifying good local
optima may require high computational effort. Lorbert et al. [47,
48] proposed an alternative generic convex penalty, the
Pairwise Elastic Net (PEN), that provides sparse feature selection
and promotes the grouping of attributes according to a
user-defined feature similarity measure (e.g. obtained from bio-
chemical interaction weights in a molecular network). PEN is a
generalization of the Elastic Net, a method providing a trade-off
between L1- and L2-penalized regressions by an adjustable par-
ameter. In PEN, this parameter can be replaced to determine the
trade-off using additional information from an attribute
similarity matrix (different instances of PEN can be defined as
long as the similarity matrix is positive semidefinite and non-
negative). Comparing PEN against other popular machine learn-
ing approaches on simulated data with a grouping structure
among the features, PEN achieved a competitive mean squared
error (MSE) and provided sparser solutions than approaches
with similar MSE.
More recently, Vlassis et al. introduced a new instance of
PEN, which penalizes differences between the ‘absolute’ values
of weights of interlinked features in a network graph. The mo-
tivation behind this approach, termed GenePEN, is that the
magnitude of a weight in a linear model reflects the predictive
value of the corresponding variable, so that the weights for
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irrelevant features are driven to zero by the penalty. By ensuring
the convexity of the penalty function, global optimal solutions
can be identified efficiently with existing optimization frame-
works. When evaluating GenePEN on simulated data and
real-word microarray data sets, in comparison with other classi-
fication methods using feature grouping, the method provided
similar predictive power and gene selections, sharing signifi-
cantly more connections within a molecular interaction net-
work. Visualization of the corresponding subnetworks enabled
a biological interpretation of disease-affected network regions,
which were enriched in known disease-related genes obtained
from literature mining.
Overall, network-based sample classification methods pro-
vide a new means to analyze complex omics data sets, allowing
researchers to identify coherent molecular network alterations
under different biological conditions. Identifying such network-
level patterns in omics data for diseases with complex
molecular manifestations can shed new light on the molecular
mechanisms of the disease and facilitate the development of
robust multifactorial biomarker signatures.
In contrast to single-molecule-based biomarker modeling, a
network-level approach has the potential to capture diverse fac-
ets of a heterogenic disease reflected via alteration patterns in
different network regions. In comparison with pathway-based
machine learning approaches, methods using genome-scaled
networks as prior knowledge may produce models that are more
difficult to interpret biologically, but which can identify a much
wider range of alterations in cellular processes (covering many
genes, proteins or metabolites without any known pathway an-
notations). Finally, network- and pathway-based classification
approaches share the main benefit of improving model robust-
ness in cross-study analyses as compared with using individual
biomolecules as features. Among these new higher-level bio-
marker signatures, network-based signatures accounting for
molecular activities over larger and algorithm-derived network
regions may often provide more robust multifactorial markers
than signatures for smaller pathways, which are typically
defined subjectively, possibly overlooking relevant functionally
related molecules in the surrounding network. However, the
model robustness will also depend on other factors, e.g. the oc-
currence of protein complexes in the studied pathway/network
(members of these complexes tend to have highly coordinated
activity, providing more robust averages) and the reliability and
completeness of the specific network or pathway data source
used (see limitations discussed in the following section).
Limitations and possible solution strategies
While pathway- and network-based analyses of omics data can
enrich the biological interpretation of complex molecular alter-
ation patterns and facilitate robust biomarker modeling, users
should also be aware of common limitations behind these
methods and possibilities to address them.
Although detailed functional annotations have been col-
lected for a large portion of genes in humans and common
model organisms, many identified genes still lack any func-
tional assignment. Consequently, a significant portion of genes
and proteins analyzed via current high-throughput measure-
ment techniques can often not be assigned to any pathway or
molecular network for systems-level analyses. Similarly, sev-
eral gene regulatory interactions and PPIs are still unknown,
and experimental techniques to identify molecular interactions
may also generate false-positive results [54]. Thus, public mo-
lecular interaction databases only cover a subset of biochemical
interactions occurring in living cells, and the reliability of re-
ported interactions varies depending on the amount and type of
associated evidence.
A further limitation of current pathway databases and
assembled molecular networks is that tissue- and cell-type spe-
cificity of molecular interactions and protein functions is typic-
ally not considered in these data resources. This can be
particularly problematic when studying diseases showing se-
lective vulnerability for specific tissues or cell types, e.g. as
found in many neurodegenerative disorders [55]. Similarly, in
many biomarker profiling studies and public omics data sour-
ces, concomitant data from different tissue and cell types for a
disease of interest is lacking, as well as longitudinal data
required to identify relevant dynamic changes during disease
pathogenesis and progression. Moreover, a variety of limita-
tions related to the specific origin, processing and storage of
specimens collected for biomarker studies may negatively im-
pact subsequent analyses and the comparability of data from
different studies. For example, studies might differ in terms of
the sample storage durations, in terms of whether the reference
tissue for tumor tissue is derived from the same patient or from
an unaffected control individual, whether a preinfarction speci-
men is accepted as a reference for the specimen obtained on in-
farct suspicion, or whether laser capture microdissection is
applied to isolate specific cells of interest rather than using het-
erogeneous cell populations.
To account for the varying reliability of public biochemical
interaction data when assembling a molecular network, various
approaches to determine confidence scores have been proposed
[56–59]. One of the most comprehensive resources is the
STRING PPI database, which allows users to filter and extract
biochemical interactions for a wide range of organisms using
different sources of evidence, as well as a combined confidence
score [60, 61].
A frequently encountered difficulty in pathway analyses is
also the conversion of the information content of public path-
way diagrams into adequate data structures for computational
investigations. Pathway structures usually contain more com-
plex layers of information than gene–gene networks, e.g. meta-
nodes representing protein complexes or gene families, and
catalysis reactions represented by edges pointing to edges.
Dedicated computational approaches are therefore required to
convert pathway diagrams into uniform network representa-
tions, e.g. using biology-driven rules as in the R/Bioconductor
software package ‘graphite’ [62].
Apart from this conversion task, building tissue-specific
pathway/network representations or assigning probabilities for
tissue specificity to the biological interactions in an existing
network is a further challenging problem because interactions
are rarely confirmed experimentally in multiple specific tissues.
Most bioinformatics approaches for assigning tissue specificity
scores to protein interactions use publicly available gene or pro-
tein expression data from large-scale tissue profiling studies
[63, 64], e.g. predicting the potential for a molecular interaction
to occur in a certain tissue depending on whether both inter-
action partners are expressed in this tissue [65]. Moreover, dedi-
cated pathway- and network-analysis methods have been
developed for tissue-specific disease gene prioritization and
gene set enrichment analysis [23, 66], which may also provide
useful filters for feature selection in machine learning methods
for sample classification.
While changes in the mean or variance of the overall mo-
lecular activity in pathways can provide robust biomarkers for
some diseases, pathways may also contain forks, and only one
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of their branches or stems may be affected in a pathological
condition. Approaches focusing on changes in the overall path-
way activity may therefore fail in detecting significant alter-
ations affecting only one pathway branch. Although network
analysis methods identifying altered subnetworks may be help-
ful in this situation (using a pathway graph as input instead of a
genome-scale molecular network), ideally, available knowledge
on distinct pathway branches or outstanding regions in a com-
plex pathway architecture should be exploited directly, e.g. by
partitioning a pathway into corresponding ‘subpathways’ and
separately analyzing their molecular alterations using existing
pathway-level bioinformatics tools.
Another challenging and still largely unsolved problem in
the analysis of alterations for pathways, networks and single
biomolecules is the distinction between omics changes repre-
senting causes or effects (or ‘drivers’ or ‘passengers’) of a dis-
ease. Apart from philosophical disagreements on how
causation should be defined [67], the discrimination between
correlated events and causally linked events on high-through-
put omics data sets is typically severely hampered by large
numbers of potential confounding variables and complex
nonlinear relationships between the attributes. Thus, conclu-
sive evidence for causal links can usually only be obtained from
in vitro and in vivo perturbation experiments rather than from
high-throughput data analysis, even when using high-quality
time-series data with large sample sizes and dedicated statistics
for identifying cause–effect relationships (e.g. the Granger caus-
ality test [68]). Prior biological knowledge, e.g. on transcription
factor–target relationships, can however enable the construc-
tion of causal graphs to check whether omics measurements
are consistent with certain causal molecular hypotheses or to
prioritize corresponding hypotheses for experimental validation
[69]. Bill Shipley has written a dedicated book on methods for
causal analysis of observational data in biology [67]. These
approaches are not only relevant for identifying drug targets
and investigating disease etiology and progression, but may
also provide useful information for the biological interpretation
of diagnostic biomarker models.
Improving incomplete pathways and networks by identify-
ing missing molecular interactions is arguably one of the most
challenging problems in this domain. Pathway definitions are
typically created in a subjective manner because no universal
predefined criteria for determining pathway membership and
boundaries are available, and the curators of the corresponding
databases are required to make judgments on the relevance of
potential pathway members. These subjective definitions may
be prejudiced and erroneous, and even networks assembled
automatically from public databases may contain biases, e.g. re-
sulting from prior subjective decisions on which putative PPIs
are of sufficient interest for experimental validation. Moreover,
in diseases the pathway topology may change, and generic
pathway databases have recently been complemented by dedi-
cated pathway maps for specific human disorders, e.g.
AlzPathway [70] for Alzheimer’s disease and PDMap [71] for
Parkinson’s disease. Because these disease-related pathway
maps typically cover the biomolecules involved in a specific dis-
order and the potentially altered network topology more com-
prehensively and accurately than generic pathway maps,
disease-specific pathways should be considered as the pre-
ferred resource for pathway-based diagnostic biomarker model-
ing (in the specific case of a known disease-associated topology
alteration, ideally, a corresponding pathway map with un-
altered topology should be used additionally as a reference in
the modeling process).
Moreover, dedicated bioinformatics techniques have been
developed to identify ‘network rewiring’ events, e.g. broken
chains or new interactions changing the pathway/network top-
ology, which remain undetected by conventional pathway ana-
lyses. Instead of assuming that molecules close to each other in
a network undergo similar changes in a disease, these
approaches identify alterations in the correlations between the
activities of these molecules as signatures for potential patho-
logical changes in network topology [72–74]. However, the top-
scoring results require experimental verification, e.g. using in
vitro disease models, and the success may strongly depend on
whether reliable prior pathway knowledge is available.
To support relevant manual pathway curation efforts, com-
putational approaches for ab initio discovery of pathways within
genetic or molecular networks have been proposed [75–78], as
well as bioinformatics methods to extend existing pathway def-
initions according to objective criteria for pathway compactness
and connectedness [79]. Moreover, various machine learning
approaches for predicting unknown PPIs using public structural
and functional information have been developed [80–84], e.g.
the authors of the PrePPI method report validation results sug-
gesting their prediction algorithm is comparable in accuracy to
high-throughput experiments [85]. For proteins with unknown
structure and few functional annotations, these in silico predic-
tion approaches are however still bound to provide limited reli-
ability, and only high-confidence biochemical interactions
should be included in networks for omics data analysis.
Finally, to reduce the influence of false-positive predictions
on network analyses, molecular interactions should not only be
prefiltered by confidence when assembling the network, but
also weighted by confidence to apply analysis techniques
exploiting these weights to score the reliability of identified net-
work alterations. In subsequent biological validation experi-
ments, investigators can then focus on verifying only the most
reliable network alteration patterns derived from the in silico
analyses.
Translating multifactorial marker models into
diagnostic tests
Pathways from omics research discoveries to clinical
diagnostic assays
High-throughput omics measurement techniques are typically
not designed for diagnostic applications, but for broad systems-
level analyses, hypothesis generation and the construction of
first tentative machine learning models for sample classifica-
tion. Such tentative models require subsequent refinement and
validation using more sensitive and reproducible measurement
techniques to evaluate their potential for diagnostic applica-
tions. For example, a sample classification model built and
cross-validated using microarray gene expression data, with an
embedded feature selection to choose only the most inform-
ative genes as predictors, can be validated using more accurate
quantitative reverse transcription polymerase chain reaction
(qRT-PCR) measurements for the subset of chosen genes.
Importantly, to avoid wrong conclusions in the evaluation of
diagnostic classification models, adequate statistical methods
have to be chosen to assess a model’s overall predictive per-
formance (quantifying how close predictions are to the actual
outcome), its calibration/reliability (measuring how close to x of
100 individuals with a risk prediction of x% have the outcome)
and its discriminative ability (determining whether individuals
with the outcome have higher risk predictions than those
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without) [86]. Owing to the inherent uncertainty associated with
diagnostic tasks, predictions should be provided in a probabilis-
tic, rather than deterministic, form [87], and the overall per-
formance should be quantified using so-called ‘proper scoring
rules’, for which the expected score is optimized when the pre-
dictive distribution agrees with the true distribution of the
quantity to be estimated (a corresponding example is the Brier
score for binary and survival outcomes [88]). Conversely, the op-
timization of models with respect to conventional discontinu-
ous non-error rates like the percentage correct classification
can provide misleading results, e.g. when the predicted proba-
bilities are close to the chosen decision threshold required for
these measures [89]. To assess the calibration of a model, the
Hosmer–Lemeshow ‘goodness-of-fit’ test can be used [90], and
the concordance statistic to quantify the discrimination ability
[91]. If a reference prediction system is already available, dedi-
cated measures of the relative improvement achieved with a
new prediction method should additionally be computed
(referred to as the ‘skill’, e.g. quantified via the Brier Skill Score
[92]). Moreover, decision-analytic approaches like decision curve
analysis [93], designed to assess the net benefit achieved making
decisions according to model predictions, should be applied if the
model is to be used to direct clinical patient management [86].
For the study design, initial power calculations are required
to ensure that sufficient sample sizes are available for all statis-
tical assessments [94]. This also involves choosing an adequate
splitting of the measured data into training, test and validation
sets and selecting suitable cross-validation or resampling tech-
niques for model optimization and evaluation (e.g. using two-
level external cross-validation [95]) [96].
Importantly, clinical validation does not only necessitate
significantly larger sample sizes than most research studies,
but also independent replication tests on data from other pa-
tient cohorts, the clear specification of the biological rationale
behind the method and a demonstration of its clinical utility. In
contrast to the regulatory framework for drugs, there are mul-
tiple pathways for the translation of omics-based tests into
validated in vitro diagnostic test devices. These tests can be
developed and validated either through review by the Food and
Drug Administration (FDA) or through validation and perform-
ance by a specific laboratory certified according to Clinical
Laboratory Improvement Amendments (CLIA) [97].
Because using established medical product development
pipelines as in pharmaceutical companies is not common prac-
tice in academia, for many biomedical research institutions an
early collaboration with an experienced industrial partner is
often advisable. Although currently no unique and widely rec-
ognized standard process for translating omics research
findings into clinical diagnostics is available, common recom-
mendations by widely recognized health organizations can be
followed. In particular, a committee by the US Institute of
Medicine has conducted a study on omics-based clinical test de-
velopment and proposed a generic process for the development
and evaluation of these tests as a recommended guideline [97].
A corresponding example process, which is briefly outlined for
illustration purposes in Figure 1 and not meant to cover all im-
portant variations, starts with the discovery phase in which a
candidate biomarker model is built on a training set, locked
down and evaluated on a test data set (this set of samples
should be completely independent from the training set). In the
following test validation phase, after institutional review board
approval and consultation with the FDA, a CLIA-certified labora-
tory defines and optimizes the diagnostic test method, clinically
and biologically validates the test on a blinded sample set and
implements the test according to current clinical laboratory
standards.
Interestingly, the authors of the guideline highlight that a
frequent shortcoming of omics-based tests is the lack of a biolo-
gical rationale behind the test—while single-molecule markers
are often known to play a role in the disease, multifactorial
omics models obtained from machine learning are often more
difficult to interpret and involve a greater risk of overfitting.
New pathway- and network-based modeling techniques as dis-
cussed in this review could therefore help to address some of
these shortcomings and provide more interpretable and robust
models as opposed to classical ‘black box’ machine learning
models.
In the following stage of the clinical development process,
the locked-down test is evaluated for clinical utility via one of
the following approaches: (i) A prospective–retrospective study
using archived specimens from previous clinical trials, (ii) a pro-
spective clinical trial in which the test (a) directs patient man-
agement, or (b) does not direct patient management [97]. The
complexity and duration of a corresponding clinical study or
trial will largely depend on the specific type of biomarker de-
veloped and the proposed clinical benefit. For diagnostic bio-
markers focused on in this review, procedures may vary
significantly depending on whether the test is designed to de-
tect the presence, severity or the subtype of a disease.
Prognostic biomarkers, which indicate the future clinical course
of a patient with regard to a specific outcome, and predictive
biomarkers, which predict the responders and the extent of sus-
ceptibility to a particular drug effect, will also require different
development and evaluation procedures than diagnostic
markers. Finally, for each type of biomarker, different clinical
benefits may be envisaged and significantly influence the de-
sign of a study, e.g. the goal to choose more appropriate treat-
ment options, or the objective to diagnose the disease earlier to
enable more effective therapies to prevent, halt or slow down
its progression.
Previous success stories in omics-based development of
diagnostic assays
A variety of multifactorial, omics-based biomarker models have
been translated successfully into diagnostic tests in recent
years, in particular, in the field of cancer sub-type stratification.
A prominent example is the Oncotype DX test to assess a wom-
an’s risk of recurrence of early-stage, estrogen-receptor-positive
breast cancer and the likelihood of benefitting from chemother-
apy after surgery. This test measures the activity of 21 genes in
tumor samples and then determines a recurrence score number
between 0 and 100 (higher scores reflect greater risk of recur-
rence within 10 years). As opposed to other diagnostic tests
using frozen samples, the Oncotype DX assay uses tumor tissue
samples that are chemically preserved and sealed in paraffin
wax (see [98, 99] for details on the sample collection and
analytics).
The development of Oncotype DX involved typical steps of
an omics biomarker profiling and top-down filtering approach:
first, by analyzing the entire transcriptome on high-throughput
microarray data and using knowledge from the literature and
genomic databases, 250 candidate marker genes were selected
[98]. The relation between the expression of these candidates
and the recurrence of breast cancer was then assessed in data
from three independent clinical studies on 447 patients. The re-
sults were used for a final filtering, providing a panel of 16 can-
cer-related genes and 5 reference genes, whose expression
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levels enabled the calculation of recurrence scores for tumor
samples via a machine learning model. This diagnostic ap-
proach was successfully validated in multiple clinical studies
and has been included in the treatment guidelines for breast
cancer by the National Comprehensive Cancer Center Network
and the American Society of Clinical Oncology.
While in the case of the Oncotype DX test, the set of required
markers could be narrowed down to a small number of genes
with prior knowledge on their relationship to the disease, for
other complex and more heterogeneous diseases, significantly
larger numbers of molecular predictors may be needed for ac-
curate diagnosis. In such cases, pathway- and network-based
modeling approaches may facilitate the generation of robust
and biologically interpretable models, which could afterward
undergo similar diagnostic test development and validation
procedures as the initial model behind the Oncotype DX assay.
Importantly, the success of the Oncotype DX approach is not an
isolated case, but other commercial diagnostic assays have
been developed and validated using similar strategies, including
MammaPrint [100], Prosigna (PAM50) [101], Mammostrat [102],
Tissue of Origin [103], AlloMap [104], Corus CAD [105] and OVA1
[106], among others.
In summary, successful translation of omics-based bio-
marker models into clinically accepted commercial diagnostic
tests has been achieved in multiple cases in the past. Given a
large number of complex diseases for which more reliable, ear-
lier and cheaper diagnostic tests are still needed, there is a
significant potential to develop improved approaches using
omics-based biomarker modeling and exploiting prior biological
knowledge from pathways and molecular networks.
Conclusions
For diseases with complex molecular manifestations, omics-
based biomarker models have the potential to better reflect
clinically relevant aspects of their heterogeneity than classical
single-molecule diagnostic markers. However, various statis-
tical limitations in high-dimensional data analysis, often result-
ing in a high risk of overfitting and restricted biological
interpretability of standard ‘black box’ machine learning mod-
els, can hamper the progress in developing new clinically useful
biomarker signatures.
Among possible strategies to reduce model complexity and
integrate prior biological knowledge into the model building
procedure, cellular pathway- and molecular network-based pre-
diction methods provide promising new routes toward more re-
liable omics-based biomarker signatures. A wide variety of
bioinformatics approaches have already been developed in re-
cent years to identify disease-associated pathway and network
alterations in omics data and use them to classify new samples.
While public molecular networks and pathway definitions also
have specific limitations that need to be addressed by the user,
e.g. by assigning confidence weights to molecular interactions,
pathway- and network-level predictive analyses often lead to
Figure 1. Example illustration of common stages during the development of omics-based diagnostic tests (simplified version of the process presented in a study by the
US Institute of Medicine [97], focusing on the major steps in the pipeline). After the transition from the second to the third phase (highlighted by the lock symbol), the
diagnostic test must be fully defined, validated and locked down. Many important variants and alternatives to the outlined example process exist, as well as different
realizations of generic steps in the process (e.g. cases in which a test directs patient management may cover different situations, depending on whether clinicians are
free to use the test result as they see fit, or whether predefined procedures have to be followed subject to contraindications and/or subject to the test results). The setup
may also vary depending on whether it is known exactly how patients would have been treated had they been randomized to the opposite arm, depending on whether
the test entails a treatment delay, and whether the adequate cutoff threshold for the test is uncertain.
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classification models with improved interpretability and robust-
ness in cross-study prediction tasks. These new systems-level
approaches will therefore provide a valuable addition to the
existing toolset for omics-based biomarker modeling.
Key Points
• Omics-based machine learning models for diagnostic
specimen classification often lack biological interpret-
ability and have limited cross-study robustness and
accuracy. Integrating prior knowledge from cellular
pathway and molecular network into these models
can help to address these shortcomings.
• Public pathway and molecular interaction databases
cover only a subset of the biochemical interactions
occurring in living cells, typically lack annotations on
tissue-specific reactions and may also contain errors.
When applying pathway or network analysis methods,
the user should be aware of these limitations and the
different options to address or alleviate them, e.g. by
using confidence weighted interactions and estimating
their tissue specificity using public gene or protein ex-
pression data.
• Pathway- and network-based machine learning meth-
ods for diagnostic specimen classification are charac-
terized by different strengths and weaknesses. While
pathway-based approaches have the benefit of provid-
ing models with high biological interpretability that
take advantage of human expert knowledge on dis-
ease-relevant cellular processes, their coverage is lim-
ited to biomolecules with known annotations. On the
contrary, network-based models are typically more dif-
ficult to interpret, but can exploit information on a
much wider range of biomolecules.
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